Amneal Pharmaceuticals, Inc.
AMRX
株式のランク
#2968
Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is... Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is a diversified pharmaceutical company involved in the development, acquisition of licenses, manufacturing, marketing, and distribution of both generic and specialized medicinal products. These offerings span a multitude of delivery formats and target a wide range of therapeutic needs. Its operations are structured into three distinct divisions: Generics, Specialty, and AvKARE. The Generics division is responsible for creating, producing, and bringing to market a diverse portfolio of complex pharmaceutical formulations. This includes oral solid doses, injectable solutions, ophthalmic preparations, liquid medications, topical applications, softgels, inhalants, and transdermal patches, all catering to a broad spectrum of medical needs. Within the Specialty division, the company concentrates on the advancement, marketing, sales, and distribution of proprietary branded pharmaceuticals. Key therapeutic areas for this segment include neurological conditions, endocrine disorders, and parasitic ailments, among others. Notable offerings include Emverm, a chewable tablet prescribed for single or mixed parasitic infections such as pinworm and various hookworms; Rytary, designed for the management of Parkinson's disease; and Unithroid, used in treating hypothyroidism. The AvKARE segment primarily serves governmental entities, particularly the Department of Defense and the Department of Veterans Affairs, supplying them with pharmaceuticals, medical and surgical supplies, and related services. Additionally, this segment engages in the bulk distribution of bottled and unit-dose pharmaceuticals under its AvKARE and AvPAK brands, alongside medical and surgical items. It also manages the packaging and large-scale distribution of medications and nutritional supplements for its retail and institutional clientele. Products from Amneal reach consumers through a network comprising wholesale suppliers, third-party distributors, hospitals, large pharmacy chains, and independent drugstores. Its operational footprint extends across the United States, India, Ireland, and other international markets. Established in 2002, the company was initially incorporated as Atlas Holdings, Inc., before adopting the name Amneal Pharmaceuticals, Inc. in 2018. Its corporate headquarters are situated in Bridgewater, New Jersey.
株価
$19.39
最終同期: 2026-10-19
時価総額
$6.19B
変化（1日）
1.09%
変化（1年）
89.36%
国
US
取引 Amneal Pharmaceuticals, Inc. (AMRX)
カテゴリー
Healthcare
Amneal Pharmaceuticals, Inc.（AMRX）のP/E比率
October 2026 時点のP/E比率 TTM 37.99
Amneal Pharmaceuticals, Inc. の最新の財務報告および株価によると、現在の P/E (TTM) は 37.99 です。2023 年末時点での P/E は -12.65 でした。
Amneal Pharmaceuticals, Inc. の P/E 比率の履歴（2014 〜 2026）
各年末のP/E比率
| 年 | P/E比率 | 変化 |
|---|---|---|
| 2026 (TTM) | 37.99 | -281.42% |
| 2024 | -20.94 | 65.56% |
| 2023 | -12.65 | 447.22% |
| 2022 | -2.31 | -103.44% |
| 2021 | 67.14 | 796.23% |
| 2020 | 7.49 | -810.26% |
| 2019 | -1.05 | -89.60% |
| 2018 | -10.14 | -188.93% |
| 2017 | 11.41 | -5.54% |
| 2016 | 12.08 | -74.68% |
| 2015 | 47.69 | 40.93% |
| 2014 | 33.84 | 0.00% |
類似企業や競合他社のP/E比率
| 企業 | P/E比率 | P/E比率の差 | 国 |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 34.96 | -7.98% |
IN
|
P/E比率の読み方
株価収益率（P/E Ratio）は、企業の株価と1株あたり利益の関係を示します。
低いが正のP/Eは、現在の評価額に対して高い利益を上げている企業を示し、割安と見なされる可能性があります。高い負の（0に近い）P/Eは、損失が大きいことを示します。
P/Eが30を超えるか、負である企業は一般に「成長株」と見なされ、投資家は将来的な成長または黒字化を期待しています。
10未満の正のP/Eを持つ企業は一般に「割安株」と見なされ、既に収益性が高いが成長の余地は小さいと見なされます。